| Name | Title | Contact Details |
|---|
Cogency Global Inc. is a New York-based company that provides registered agent, process agent, corporate compliance, and transactional legal support services. Founded in 1980, it serves clients worldwide across various industries, including nonprofits. The company employs around 300 people and generates approximately $63 million in annual revenue. With expertise in over 4,000 jurisdictions, Cogency offers localized services and maintains a multilingual team for 24-hour support. The company provides a wide range of services tailored for law firms, nonprofits, lenders, and businesses. These include registered and process agent services, corporate compliance and filings, and transactional support. Cogency also offers international solutions with country-specific expertise to ensure smooth operations. Its technology-enabled tools enhance service delivery, featuring data-driven reporting and online platforms for document organization and compliance tracking.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Midwest Employers Casualty (MEC), a Berkley Company, is a prominent provider of tailored excess workers compensation insurance products for self-insured employers, groups, captives, and insurance companies across the United States. Headquartered in Chesterfield, Missouri, MEC is part of W. R. Berkley Corporation and is recognized for its strong financial stability, with an A+ (Superior) rating from A.M. Best. MEC specializes in excess of loss workers compensation insurance, offering customized solutions that prioritize worker recovery and effective claims outcomes. The company utilizes its proprietary XCEL Analytics® platform, which employs AI for predictive analytics to identify potential large-loss claims and improve claims management. MECs core offerings include self-insured excess coverage, large deductible programs, and excess reinsurance, with a focus on industries such as healthcare. The company is committed to innovation, integrity, and collaboration, ensuring measurable results for its clients.
Your trusted partner in home financing, banking, and wealth-building. We offer innovative lending options, full-service banking, and personalized guidance to help you reach your financial goals.